DOCSLIB.ORG

RH DH HC HP 1 1.01 Ketamine Injection 50Mg/Ml Thiopentone

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RH DH HC HP 1 1.01 Ketamine Injection 50Mg/Ml Thiopentone GUYANA EDL 2009-2010 Product Dose Form Strength RH DH HC HP 1 Anaesthetics 1.01 General Anaesthetics and oxygen 1.01.01 Intravenous Ketamine Injection 50mg/ml Pdr. for Thiopentone Sodium 0.5g injection Propofol Injection 10mg/ml 1.01.02 Inhalation Halothane Vol. liquid Soda lime Pellet Nitrous oxide Gas Complementary Drugs Enflurane Vol. liquid 1.02 Local Anaesthetics Bupivacaine Injection 0.50% 0.5% in dextrose Bupivacaine (spinal) heavy Injection 7.5% Ethyl chloride Spray Lidocaine Spray 10% Lidocaine (hydrochloride) Injection 1%, 2% Lidocaine (hydrochloride), Injection 5%/2ml spinal heavy Lidocaine hydrochloride + Injection 2% + 1:80 000 epinephrine (den.) Preoperative Medication and Sedation for Short-Term Procedures 1.03 Midazolam Injection 5mg/ml Diazepam Tablet 5mg 2 Analgesics, Antipyretics, Nonsteroidal Anti-Inflammatory Drugs (NSAID); Drugs 2.01 Non-Opioids Acetylsalicylic acid Tablet 500mg Diclofenac sodium Injection 25mg/ml * Diclofenac sodium Tablet 25mg, 75mg Diclofenac sodium Suppositories 50 mg Ibuprofen Tablet 200, 400 mg 60 mg, Paracetamol Suppositories 120mg Paracetamol Tablet 500mg Paracetamol Syrup 120mg/5ml Complementary Drugs Metamizole sodium Injection 500 mg/ml 2.02 Opioid Analgesics Codeine Tablet 30mg Co-codamol Tablet 30 mg+ 500 mg (codeine+ paracetamol) Morphine Injection 10mg/ml Morphine Oral Sol. 10mg/5ml Morphine Tablet 10mg Morphine SR (10a) Tablet 30mg Complementary Drugs Fentanyl (10a) Injection 0.5mg/10 ml Methadone Injection 10 mg/ml Methadone Tablet 5mg 50mg/ml, Pethidine Injection 100mg/2ml 2.03 Opiod antagonist Naloxone Injection 0.4mg/ml 2.04 Drugs used to treat gout Ibuprofen Tablet 600 mg For Prophylaxis Allopurinol Tablet 100mg,300mg 2.05 Disease modifying agents used in rheumatoid disorders (DMARDSs) Hydroxychloroquine Tablet 150mg Complementary Drugs Azathioprine Tablet 50 mg Methotrexate Tablet 2.5mg,10 mg Sulphasalazine Tablet 500 mg 3 Antiallergics and Drugs used in Anaphylaxis Adrenaline Injection 1 mg/ml Chlorpheniramine maleate Injection 10mg/ml Chlorpheniramine maleate Tablet 4mg Chlorpheniramine maleate Syrup 2mg/ml Dexamethasone Injection 4mg/ml Pwd. for Hydrocortisone 100mg injection Prednisolone Tablet 5mg ,25 mg Prednisolone Syrup 5mg/ml 4 Antidotes and Other Substances Used in Poisonings 4.01 Non-specific Charcoal activated (carbon Pdr. adsorbent) Fuller's earth Pdr. 4.02 Specific Acetylcysteine Injection 200mg/ml Anti-snake Injection * Venom(polyvalent) Atropine Injection 1mg/ml Calcium gluconate Injection 100mg/ml Desferrioxamine Injection 500mg Dimercaprol Injection 50mg/ml Flumazenil Injection 0.1mg/ml Naloxone Injection 0.4mg/ml Pralidoxime Mesilate Injection 200mg/ml Protamine Sulphate Injection 10 mg/ml Sodium calcium edetate Injection 200mg/ml Sodium nitrite Injection 30% Sodium Thiosulphate Injection 50% 5 Anticonvulsants Carbamazepine Tablet (scored)200mg * Carbamazepine Syrup 100mg/5ml * Diazepam Injection 5mg/ml Magnesium Sulphate Injection 50% in 2ml * Phenobarbital Tablet 30mg, 100mg Phenobarbital Elixir 15mg/5ml Phenobarbital Injection 200mg/ml Phenytoin sodium Tablet 25mg, 100mg Phenytoin sodium Syrup 25mg/5ml Phenytoin sodium Injection 50 mg/ml Sodium valproate Tablet 200mg Sodium valproate Syrup 200mg/5ml Complementary Drugs 300 mg & 600 Gabapentin Capsule mg 6 Anti-Infective Drugs 6.01 Anthelmintics 6.01.01 Intestinal Anthelmintics Mebendazole Tablet 100mg, 500mg Mebendazole Suspension 100 mg/5ml Thiabendazole Tablet 500mg 6.01.02 Antifilarials Albendazole Tablet 200, 400mg Diethylcarbamazine citrate Tablet 50mg, 100mg 6.02 Antimicrobials 6.02.01 Oral Liquids Amoxicillin Suspension 125mg / 5ml Chloramphenicol Suspension 125 mg/ 5ml Co - trimoxazole Suspension 200mg+ 40mg/ 5ml Cloxacillin Suspension 125mg / 5ml Erythromycin Suspension 125mg / 5ml Metronidazole Suspension 125mg / 5ml Phenoxymethylpenicillin Suspension 125mg/5ml Complementary Drugs (B,D) Amoxicillin+clavulanic acid Suspension 125 / 31mg / 5ml Azithromycin Suspension 200mg/5ml Cefuroxime Suspension 125mg/5ml Cephalexin Suspension 125mg/5ml 6.02.02 Tablets / Capsules Amoxicillin Tablet 250mg, 500mg Cefixime Tablet 200 mg Chloramphenicol Capsule 250mg, Ciprofloxacin Tablet 500 mg Cloxacillin Capsule 250mg, 500mg Co -trimoxazole Tablet 400mg + 80mg Co -trimoxazole Tablet 800mg + 160mg Doxycycline Tablet 100mg Erythromycin Tablet 250mg, 500mg Metronidazole Tablet 250 mg Phenoxymethylpenicillin Tablet 250mg Complementary Drugs Azithromycin Tablet 250mg Cephalexin Tablet 250 mg Cefuroxime Tablet 250mg Clindamycin Tablet 150mg, 300mg Ofloxacin Tablet 200mg 6.02.03 Injections Pdr. for Ampicillin 500mg, 1g injection Pdr. for Benzathine benzylpenicillin 1.2 IU injection Pdr. for 600mg (1 MU), Benzylpenicillin (Crystapen) injection 1g(5MU) Ceftriaxone Injection 500mg, 1G Cefuroxime Injection 250mg Pdr. for Chloramphenicol 250mg, 500mg injection Pdr. for Cloxacillin 500mg injection Gentamycin Injection 10mg, 40mg/ml Metronidazole Injection 500mg / 100ml Pdr. for Procaine penicillin 1MU, 3 MU injection Complementary Drugs Amikacin Injection 250mg/ml Cefotaxime Injection 1 g Clindamycin Injection 150mg/ml Spectinomycin Injection 2 G Restricted Indications Ciprofloxacin Injection 2mg /ml Co-trimoxazole Injection 480mg /ml 6.03 Antileprosy Drugs Clofazimine Capsule 50 mg ,100mg Dapsone Tablet 50mg, 100mg Rifampicin Tablet/capsule 150mg, 300mg Prednislone Tablet 25 mg 6.04 Antituberculosis Drugs Ethambutol Tablet 400mg Isoniazid Tablet 100mg, 300mg Pyrazinamide Tablet 500mg Pyridoxine Tablet 50mg Rifampicin Tablet 150mg, 300mg Streptomycin Injection 1g Combination Therapy Rifampicin+ Isoniazid (RH Tablet 150mg + 150 mg 150/150 ) Rifampicin+ Isoniazid + 150mg+ 75 Ethambutol (RHE Tablet mg+ 275 mg 150/75/275 ) 150mg+ Rifampicin+ Isoniazid+ 75mg+ Pyrazinamide+ Etambutol Tablet 400mg+ (RHZE 150/75/400/275 ) 275mg Ethambutol +Isoniazid (EH Tablet 400mg +150 mg 400/150) Reserve second-line drugs used to treat (MDR-TB) Please contact the Director TB programme for supplies of these drugs Ciprofloxacin Tablet 500mg Ethionamide Tablet 250mg Kanamycin Injection 1 g Ofloxacin Tablet 400mg p-aminosalicylic acid Tablet 500mg Capreomycin Injection 1 g Cycloserine Injection 1 g 6.05 Antifungal Drugs Fluconazole Tablet 150mg Fluconazole Suspension 50mg/5ml Griseofulvin Tablet 125 mg, 500 mg Ketoconazole Tablet 200mg Nystatin Suspension 100 000 IU /ml Complementary Drug Pdr. for Amphotericin B 50mg injection 6.06 Antiamoebic and Antigiardiasis Drugs Metronidazole Tablet 250mg Metronidazole Injection 500 mg Metronidazole Suspension 125mg /5ml 6.07 Antileishmaniasis Drugs Pdr. for Pentamidine isethionate 300mg Injecton Complementary Drug Pdr. for Amphotericin B 50mg injection 6.08 Antimalarial Drugs Arthemeter/Lumefantrine Tablet 20mg/120mg Chloroquine Tablet 100mg, 150mg base Chloroquine syrup 50mg/5ml Primaquine Tablet 7.5mg, 15mg Reserve second-line drugs used to treat Malaria) Artesunate Tablet 150mg Clindamycin Tablet 150mg, 300mg * Doxycycline Tablet 100mg * Mefloquine Tablet 250mg Quinine Tablet 300mg Quinine Injection 300mg/ml ** 6.09 Antiviral Drugs 6.09.01 Drugs used in the treatment of Herpes Acyclovir Tablet 200mg * Complementary Drug Famicyclovir Tablet 125mg, 500mg Valaciclovir Tablet 500mg (for topical and opthalmic applications see sections 13.06 and 21.01 respectively) 6.10 Antiretrovirals 6.10.01 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Abacavir ABC Tablet 300mg * Abacavir ABC Solution 100 mg/ 5ml * Lamivudine (3TC) Tablet 150mg * Lamivudine (3TC) Suspension 50mg / 5ml * Stavudine (d4T) Capsule 15mg,30mg, 40mg * Zidovudine AZT Tablet 100,300mg * Zidovudine AZT Suspension 5mg/5ml * Combination Therapy Zidovudine +Lamivudine Tablet 150 mg +300 mg (AZT +3TC) Tenofovir + Emcitrabine Tablet 300 + 200mg * (TDF+ FTC 300/200 mg) Complementary Drug Didanosine Tablet 150mg, 200mg * 6.10.02 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 200 mg,400 mg, 600 Efavirenz Tablet * mg Nevirapine Tablet 200mg * Nevirapine Suspension 50mg / 5ml * 6.10.03 Protease Inhibitors Lopinavir + Ritonavir Capsule 200mg /50 mg * Lopinavir + Ritonavir Oral solution 400 + 100mg/5ml * 6.11 Anti-pneumocystosis and antitoxoplasmosis Drugs Dapsone Tablet 50 mg,100mg * Sulfamethoxazole + Tablet 960 mg * Trimethoprim Sulfamethoxazole + 80mg+16mg / ml Injection * Trimethoprim (96mg/ml) 7 Antimigraine Drugs 7.01 Treatment of Acute Attacks Ibuprofen Tablet 400mg Paracetamol Tablet 500mg Complementary Drug 25mg+50mg+ Sumatriptan Succinate Tablet 100mg 8 Antineoplastics, Immunosupressives and Drugs used in Palliative Care 8.01 Immunosuppressive Drugs Azathioprine Capsule 50 mg 8.02 Cytotoxic Drugs (1,11) Anti metabolites Fluorouracil Injection 25mg/ml Methotrexate Injection 50 mg Methotrexate Tablet 2.5 mg,10 mg Alkylating Drug Pdr. for Cyclophosphamide 500 mg Injection Cyclophosphamide Tablet 25 mg Vincristine(1,4) Injection 1mg / ml Cytotoxic Antibiotic Pdr. for Doxorubicin Injection 50mg Doxorubicin Injection 10mg/vial Other Anti- Neoplastics Cisplatin Injection 1mg/ml Complementary Drugs Paclitaxel Injection 6mg/ml 8.03 Hormones and Antihormones Prednisolone Tablet 5mg Tamoxifen Tablet 10mg 8.04 Drugs used in palliative care These drugs are included in the relevant sections of this list, according to their therapeutic uses. 9 Antiparkinsonism Drugs Benaztropine Mesylate Injection 1mg/ml Trihexyphenidyl Tablet 2mg, 5mg Hydrochloride
Load more

Recommended publications
  • Comparative Study of Different Doses of Rocuronium Bromide For
    MedDocs Publishers Annals of Anesthesia and Pain Medicine Open Access | Research Article Comparative study of different doses of rocuronium bromide for endotracheal intubation Nidhi V Sardhara1*; Sonal A Shah2; Dhaval P Pipaliya3; Shivansh Gupta3 1SVP hospital, 13th floor, Room no 13125, Near Ellis bridge, Ahmedabad, Gujarat-380006 2Assistant Professor, Department of anesthesia, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India 3First year Resident, Department of anesthesia, Smt. NHL Municipal Medical College, Ahmedabad, Gujarat, India *Corresponding Author(s): Nidhi V Sardhara Abstract SVP hospital, 13th floor, Room no 13125, Near Ellis Background: Endotracheal intubation is one of such bridge, Ahmedabad, Gujarat-380006 development without which general anesthesia cannot be Tel: +91-9428-44-7878, Fax: 7926-57-8452 considered safe for any major surgery particularly head and Email: [email protected] neck, thoracic and abdominal surgeries. Ever since the ad- vent of anesthesia, anesthesiologists have been in search of an ideal muscle relaxants which can provide ideal intu- bating conditions in ultrashort duration with minimal side effects. Rocuronium bromide provides fast onset of action, Received: Mar 11, 2020 an intermediate duration of action and rapid recovery, good Accepted: Apr 24, 2020 to excellent intubating conditions at doses having minimal Published Online: Apr 30, 2020 or no haemodynamic changes. Present study is to compare the effect of different doses (0.6 mg/kg, 0.9 mg/kg, 1.2 mg/ Journal: Annals of Anesthesia and Pain Medicine kg) of Rocuronium bromide for endotracheal intubation at Publisher: MedDocs Publishers LLC 60 seconds. Online edition: http://meddocsonline.org/ Material and methods: This study was carried out by Copyright: © Sardhara NV (2020).
    [Show full text]
  • Suxamethonium Chloride 2016
    SUXAMETHONIUM CHLORIDE 2016 Alert Intubation, suction and ventilation equipment MUST be ready prior to administration of suxamethonium. A medical officer/nurse practitioner (preferably two personnel) experienced in advanced neonatal airway management techniques should be present when the medication is being administered. Risk of cardiac arrest from hyperkalemic rhabdomyolysis Indication Elective endotracheal intubation. Action Short-acting, depolarising neuromuscular blocker. It acts as an acetylcholine antagonist at nicotinic acetylcholine receptors at neuromuscular junctions, resulting in persistent depolarisation of the motor end plate. Drug Type Neuromuscular blocking agent (depolarising) Trade Name Suxamethonium Chloride Injection BP Presentation 100 mg/2 ml ampoule. Dosage/Interval IV ( preferred): 2 mg/kg (up to 3 mg/kg) IM (only if IV is not accessible): 3–4 mg/kg9 (onset of action can be delayed up to 3 minutes and duration of action is up to 15 minutes) Route IV, IM Maximum Dose IV: 3 mg/kg/dose; IM: 4 mg/kg/dose Preparation/Dilution IV: Draw up 1 mL (50 mg of suxamethonium) and add 9 mL sodium chloride 0.9% to make final volume 10 mL with a concentration of 5 mg/mL. IM: Administer undiluted. Administration IV: Rapid injection at proximal cannula site. IM: Administer in anterior thigh muscle. Monitoring Continuous cardiorespiratory monitoring. Monitor temperature, blood pressure, oxygenation and assisted ventilator status. Contraindications Hyperkalaemia Family history of malignant hyperthermia Skeletal muscle myopathy Hypersensitivity to suxamethonium Precautions Anaphylaxis: Severe anaphylactic reactions (some life-threatening and fatal) have been reported. Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Zambia Essential Medicine List (Zeml) 03 2013
    ZAMBIA ESSENTIAL MEDICINE LIST (ZEML) 03 2013 Drug Presentation Level VEN 1 Drugs used in anaesthesia 1.1. Drugs used in general anaesthesia 1.1.1 Intravenous and intramuscular anaesthetics 1.1.1.1 Ketamin injection 10mg/ml (10 ml) II-IV V 1.1.1.2 Thiopentone sodium powder for reconstitution 1g and 5g vials II-IV V 1.1.2 Inhalation anaesthetics 1.1.2.1 Halothane inhalation II-IV V 1.1.2.2 Nitrous oxide medical gas II-IV E 1.1.3 Muscle relaxants 1.1.3.1 Suxamethonium chloride injection 50mg/ml, (2ml) II-IV V 1.1.4 Anticholinesterases 1.1.4.1 Neostigmine injection 2.5mg/ml, (1ml) II-IV V 1.2 Drugs used in local anaesthesia 1.2.1. Lignocaine injection 1% (10ml, 50ml) I-IV V 1.2.2 Lignocaine + adrenaline dental cartridge injection 2% (1 in 80,000) II-IV V 1.3 Drugs used in spinal anaesthesia 1.3.1 Bupivacaine/glucose injection 0.5%, (4ml) IV E 1 Drug Presentation Level VEN 2. Drugs acting on the gastrointestinal system 2.1 Antacids 2.1.1 Aluminium hydroxide gel, chewable tablets I-IV E 2.12 Magnesium trisilicate Compound chewable tablets, mixture I-IV E 2.2. Antispasmodics 2.2.1 Hyoscine butyl bromide injection 20mg/ml, (1ml) II-IV E 2.2.2 Propantheline bromide tablets 15mg I-IV E 2.3 Ulcer healing drugs 2.3.1 Cimetidine tablets 200mg II-IV E 2.3.2 Omeprazole tablets 10mg, II-IV E 2.3.3 Ranitidine tablets 150mg II-IV E 2.3.4 Tripotassium dicitratobismuthate tablets 120mg II-IV E 2.3.5 Clarithromycin tablets 250mg II-IV E 2.4.
    [Show full text]
  • Muscle Relaxants
    Muscle relaxants ●cause relaxation of striated (voluntary skeletal) musculature (in contrast to spasmolytics which relax unstriped musculature) Classification of myorelaxants 1. Neuromuscular blocking drugs ●periferial (direct) myorelaxants: interact with acetylcholine nicotinic (N) receptors of skeletal musculature a) stabilizing myorelaxants – N-receptors antagonists b) depolarizing myorelaxants – N-receptors agonists ●continuous N-receptors stimulation depolarization of cells functional antagonism: further leading of impulses imposible, no muscle contraction c) indirect myorelaxants: botulinum toxin ●irreversibly inhibits acetycholine releasing 2. Central muscle relaxants ●acts in CNS ●structurally heterogenic group ●compounds with various mechanisms of action Stabilizing myorelaxants ●N-receptors antagonists in skeletal muscle cells ●usage: surgical operative measures (often as a part of some form of anaesthesia) ●structures derived from curare alkaloids Curare: arrow poison of South American Indians ●preparation from various plants ●contained a complex mixture of alkaloids Curare classification: according to preparation and package in which it was shipped to Europe 1. Tubocurare: in hollow bamboo rods 2. Calebase curare: in bottle-shaped cucurbits (gourds, calabashes - from plants of genus Strychnos) 3. Pot curare: in ceramic vessels Structural types: 1. Benzyltetrahydroisoquinolines: tubocurarine (from tubocurare) atracurium besylate (synthetic) mivacurium besylate (synthetic) etc. 2. Indole derivatives: toxiferine C alcuronium chloride 3. Steroids with basic substituents: vecuronium bromide pancuronium bromide rocuronium bromide 1. Benzyltetrahydroisoquinolines H3C O H C O O CH3 3 H3C H + H3C H C O O H3C N O 3 OH H C 3 O O H3C H H H + CH + N 3 O O N OH O CH3 N CH3 O O O H3C O CH3 O CH3 tubocurarine atracurium ●used as besylate Tracrium ® inj.
    [Show full text]
  • 2018 Product List Expertise in Injectables
    2018 Product list Expertise in injectables Flucloxacillin ................................................................................ ................................................... 250 mg Antibiotics ................................................................................ ................................................... Flucloxacillin 500 mg Amoxicillin ....................................................................................... .................................................... 250 mg ................................................................................ .................................................................. Flucloxacillin 1 g Amoxicillin ....................................................................................... .................................................... 500 mg ..................................................................................... .................................................................. Fosfomycin 1 g Amoxicillin ....................................................................................... ................................................................... 1 g ..................................................................................... .................................................................. Fosfomycin 4 g Amoxicillin ....................................................................................... ................................................................... 2 g Gentamicin ......................................................................................
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Murexal 10 mg/mL solution for injection in pre-filled syringe 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for injection contains 10 mg of suxamethonium chloride anhydrous (as 11 mg of suxamethonium chloride dihydrate). Each 10 ml pre-filled syringe contains 100 mg of suxamethonium chloride anhydrous (as 110 mg of suxamethonium chloride dihydrate). Excipient with known effect: Each ml of solution for injection contains 2.79 mg equivalent to 0.12 mmol of sodium. Each 10 ml pre-filled syringe contains 27.9 mg equivalent to 1.2 mmol of sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection (injection). Clear and colourless solution. pH: 3.0 – 4.5 Osmolality: 250-350 mOsm/Kg 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Murexal is indicated as a muscle relaxant to facilitate endotracheal intubation during induction of general anaesthesia or emergency situations, in adults and paediatric population above 12 years of age. 4.2 Posology and method of administration Suxamethonium should be administered only by or under close supervision of an experienced clinician (anaesthesist, intensivist, emergency physician) familiar with its action, characteristics and hazards, who is skilled in the management of intubation and artificial respiration and only where there are adequate facilities for immediate endotracheal intubation with administration of oxygen by intermittent positive pressure ventilation. It is given intravenously after anaesthesia has been induced and should not be administered to the conscious patient. Posology Adults To achieve endotracheal intubation, suxamethonium chloride is usually administered by bolus intravenous injection in a dose of 1 mg/kg body weight.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. TRACRIUM (atracurium besilate 10 mg/mL injections (2.5 mL and 5.0 mL)) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5 mL ampoule contains 25 mg atracurium besilate, each 5 mL ampoule contains 50 mg atracurium besilate. TRACRIUM 2.5 mL and 5.0 mL injections contain no preservative. 3. PHARMACEUTICAL FORM TRACRIUM injection is a clear, faintly yellow, sterile, aqueous solution in a glass ampoule containing 10 mg/mL atracurium besilate. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications TRACRIUM is a highly selective, competitive or non-depolarising neuromuscular blocking agent which is used as an adjunct to general anaesthesia to enable tracheal intubation to be performed and to relax skeletal muscles during surgery or controlled ventilation, and to facilitate mechanical ventilation in Intensive Care Unit (ICU) patients. 4.2 Dose and method of administration Use in adults Injection TRACRIUM is administered by intravenous injection. The dosage range for adults is 0.3 to 0.6 mg/kg (depending on the duration of full block required) and will provide adequate relaxation for 15 to 35 minutes. Endotracheal intubation can usually be accomplished within 90 seconds from the intravenous injection of 0.5 to 0.6 mg/kg. Full block can be prolonged with supplementary doses of 0.1 to 0.2 mg/kg as required. Successive supplementary dosing does not give rise to accumulation of neuromuscular blocking effect. Spontaneous recovery from the end of full block occurs in about 35 minutes as measured by the restoration of the tetanic response to 95% of normal neuromuscular function.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]